ProShares Ultra QQQ ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? ProShares Ultra QQQ ETF trades at $99.16 (market cap $15.83B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: ProShares Ultra QQQ ETF is far larger — about 4× Relay Therapeutics Inc. Common Stock's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| QLD | RLAY | |
|---|---|---|
Market Cap | $15.83B | $3.94B |
Volume | 3,097,438 | 3,432,928 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $20.75 |
52-Week Low | $57.16 | $6.03 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | — | $3.06B |
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, offering amplified returns during market rallies while being less volatile than 3x leveraged alternatives. Recent institutional buying activity and media coverage highlight continued investor interest in leveraged tech exposure.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $99 and resistance at $101. While the bullish moving average alignment suggests upward momentum, overbought RSI levels indicate potential near-term consolidation. Key risks include market volatility, Federal Reserve policy impacts, and the inherent leverage decay characteristic of daily reset ETFs.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →